Drug study for hard-to-treat CML or Ph+ ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 1 study tests HQP1351 for people with CML or Ph+ ALL that has not responded well to standard targeted pills (TKIs), or those who could not tolerate them. It’s designed to see whether the treatment can work and how safe it is for this difficult-to-treat group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have CML (any stage) or Ph+ ALL, and your cancer has not responded well or you couldn’t tolerate at least one TKI, in some groups after multiple TKIs
- If you have T315I mutation, you may have been treated with fewer TKIs than other patients (the “how many prior pills” rule may be different)
- You must be willing and able to sign consent and follow study procedures
- Your general health checks must be okay (adequate blood/organ function, heart pumping strength, and blood chemistry targets)
- Your heart rhythm test (ECG) must show a “normal” corrected QT interval for your sex
- You can’t recently take certain medicines (especially recent TKI or chemo timing, or drugs known to interact with HQP1351)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of four drugs (LP-118, ponatinib, dexamethasone, and blinatumomab) to treat a specific type of blood cancer called Philadelphia-chromosome positive acute lymphoblastic leukemia (ALL). The study aims to see if this combination is safe and effective in newly diagnosed adults.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
This study tests a combination of chemotherapy, targeted pills (imatinib or ponatinib), and a targeted immunotherapy (blinatumomab) before a stem cell transplant for adults with a specific type of leukemia called Philadelphia chromosome-positive ALL. The goal is to find the best treatment approach.
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
This study tests an experimental pill (HMPL-506) for people with certain types of leukemia (AML or ALL) that have not responded to standard treatments. The pill targets specific gene changes (MLL rearrangement or NPM1 mutation) to try to kill the cancer cells.
Hear when a new Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.